Ekso Bionics Holdings Inc
$ 10.00
3.84%
14 Apr - close price
- Market Cap 35,633,800 USD
- Current Price $ 10.00
- High / Low $ 10.00 / 9.21
- Stock P/E N/A
- Book Value 2.54
- EPS -4.91
- Next Earning Report 2026-05-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.34 %
- ROE -1.08 %
- 52 Week High 13.50
- 52 Week Low 2.73
About
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the United States and internationally. The company is headquartered in Richmond, California.
Analyst Target Price
$9.50
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-23 | 2025-10-28 | 2025-07-28 | 2025-04-28 | 2025-03-03 | 2024-10-28 | 2024-07-29 | 2024-04-29 | 2024-03-04 | 2023-10-26 | 2023-07-27 | 2023-04-27 |
| Reported EPS | -1.46 | -0.54 | -1.24 | -0.12 | -0.14 | -0.1 | -0.13 | -0.2 | -0.22 | -0.24 | -0.31 | -0.33 |
| Estimated EPS | -0.06 | -0.085 | -0.08 | -0.16 | -0.08 | -0.1 | -0.13 | -0.16 | -0.11 | -0.31 | -0.28 | -0.31 |
| Surprise | -1.4 | -0.455 | -1.16 | 0.04 | -0.06 | 0 | 0 | -0.04 | -0.11 | 0.07 | -0.03 | -0.02 |
| Surprise Percentage | -2333.3333% | -535.2941% | -1450% | 25% | -75% | 0% | 0% | -25% | -100% | 22.5806% | -10.7143% | -6.4516% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-04 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.03 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: EKSO
2026-04-13 10:10:35
A new report by DataM Intelligence, "Sports Exoskeleton Market Size 2026," forecasts significant growth for the global sports exoskeleton market between 2026 and 2033, driven by advancements in wearable robotics for rehabilitation, performance enhancement, and injury prevention. Key players like Sarcos Technology and Robotics, Ekso Bionics, German Bionic, and CYBERDYNE Inc. are expanding their offerings with AI-driven systems, lightweight materials, and adaptive assistance algorithms. The market is expected to reach US$1543.98 million by 2033, growing at a CAGR of 26.88%.
2026-04-12 15:09:18
This is the Q1 2025 Earnings Call Transcript for Ekso Bionics Holdings, Inc. (NASDAQ:EKSO). The transcript covers the company's financial results and a discussion of their performance during the first quarter of 2025.
2026-04-10 21:09:56
Ekso Bionics Holdings, Inc. filed an amended annual report (10-K/A) for 2025 to disclose detailed Part III information, including executive and director biographies, compensation, ownership stakes, and auditor fees. This amendment was necessary because a proxy statement would not be filed within 120 days of the fiscal year-end. The report reveals CEO Scott Davis's 2025 compensation of $908,750 and outlines the company's governance structure, including board committees, independence standards, and a Dodd-Frank-compliant clawback policy.
2026-04-09 19:39:57
Mink Brook reporting persons have disclosed beneficial ownership of 190,596 shares, representing a 5.4% stake in Ekso Bionics (NASDAQ: EKSO), as detailed in a recent SCHEDULE 13G SEC filing. This ownership is attributed to Mink Brook Partners LP, with shared voting and dispositive power among Mink Brook Capital GP LLC, Mink Brook Asset Management LLC, and William Mueller, calculated based on 3,563,381 shares outstanding as of February 23, 2026. The filing explicitly disclaims beneficial ownership for Section 13(d) purposes by Mr. Mueller and Mink Brook Capital GP LLC, except for their pecuniary interests.
2026-04-07 12:39:24
Ekso Bionics Holdings Inc (EKSO) is currently considered to be in the "Fair zone" with a forward PS ratio of 1.32. Its fair price, according to a relative valuation method, ranges from $2.36 to $18.71. The company's P/S ratio of 1.27 is 13.74% above the industry average, which the analysis suggests is unsustainable given its revenue growth of -38.31%.
2026-03-21 18:39:23
Ekso Bionics (NASDAQ:EKSO) COO Jason C. Jones purchased 1,308 shares of company stock for $15,499. This transaction occurred as the stock price had declined by 8.8% over the past week, although it has seen a 56% return over the last year. The company also announced a $5.9 million private placement and a non-binding merger agreement with Applied Digital Cloud to form ChronoScale Corporation, leading to a downgrade of its stock rating from H.C. Wainwright.
